Seres Therapeutics (MCRB) Research & Development (2016 - 2025)
Historic Research & Development for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $12.6 million.
- Seres Therapeutics' Research & Development fell 2335.36% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.2 million, marking a year-over-year decrease of 3286.77%. This contributed to the annual value of $64.6 million for FY2024, which is 4506.66% down from last year.
- Latest data reveals that Seres Therapeutics reported Research & Development of $12.6 million as of Q3 2025, which was down 2335.36% from $12.9 million recorded in Q2 2025.
- Seres Therapeutics' Research & Development's 5-year high stood at $46.8 million during Q2 2023, with a 5-year trough of -$17.0 million in Q4 2022.
- Moreover, its 5-year median value for Research & Development was $25.2 million (2023), whereas its average is $25.9 million.
- In the last 5 years, Seres Therapeutics' Research & Development tumbled by 14638.93% in 2022 and then surged by 23515.75% in 2023.
- Seres Therapeutics' Research & Development (Quarter) stood at $36.8 million in 2021, then plummeted by 146.39% to -$17.0 million in 2022, then soared by 235.16% to $23.0 million in 2023, then tumbled by 44.27% to $12.8 million in 2024, then dropped by 1.75% to $12.6 million in 2025.
- Its last three reported values are $12.6 million in Q3 2025, $12.9 million for Q2 2025, and $11.8 million during Q1 2025.